Dexcom (DXCM) Proxy filing summary

Executive summary

• Achieved $4.66 billion in revenue for 2025, up 16% from 2024, with $2.80 billion in gross profit and $836.3 million in net income, reflecting strong operational and financial performance.

• Expanded global customer base to approximately 3.5 million, driven by new product launches, broader access, and enhanced manufacturing capabilities.

• Launched Dexcom G7 15 Day in the US and received FDA clearance for Dexcom Smart Basal, supporting innovation and market leadership.

• Approved a $750 million share repurchase program, returning $500 million to shareholders in 2025.

• Board leadership transitioned with Jacob Leach as CEO and Kevin Sayer as Executive Chairman, ensuring continuity and strategic oversight.

Voting matters and shareholder proposals

• Election of twelve directors to serve until the 2027 annual meeting, all current directors and nominees recommended for re-election.

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation for fiscal year 2025, with board recommending approval.

Board of directors and corporate governance

• Board comprises twelve members with diverse backgrounds in healthcare, technology, and business, with 10 of 12 directors independent.

• Board committees (Audit, Compensation, Nominating and Governance, Technology) are fully independent and meet regularly.

• Lead Independent Director and Executive Chairman roles are separated to enhance oversight and strategic guidance.

• Annual board and committee self-evaluations, director orientation, and continuing education are in place.

• Stockholder engagement includes regular meetings, feedback review, and transparent communication channels.